Safety and Efficacy of Deep Transcranial Magnetic Stimulation (dTMS) in childhood and adolescent onset obsessive compulsive disorder

Safety and Efficacy of adjunctive Deep Transcranial Magnetic Stimulation (dTMS) in childhood and adolescent onset obsessive compulsive disorder: A Sham controlled fMRI study - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/055682

Enrollment

Registered

2023-07-25

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F422- Mixed obsessional thoughts and acts

Interventions

Intervention1: Deep transcranial magnetic stimulation(dTMS): The helmet with H7 dTMS coil will be placed on the head of the patient. The helmet is designed so that the maximal stimulation is delivered

Eligibility

Inclusion criteria

Inclusion criteria: 1.Diagnosis of Obsessive-Compulsive Disorder using Diagnostic Criteria for Research (DCR) of ICD 10 DCR (World Health Organization, 1993) 2.Age group of 10-20 years with either sex 3.Childrenâ??s Yale Brown obsessive-compulsive scale (CY-BOS) score of 15 or above 4.Patients (>=18years) or Parents giving written informed consent (

Exclusion criteria

Exclusion criteria: 1.Co-morbid severe depression as measured by a HAM-D score of 23 or more 2.Patients with co-morbid neurological or any other psychiatric disorder 3.Patients who cannot undergo MRI scan 4.Colour blind, as indicated by Ishiharaâ??s charts

Design outcomes

Primary

Measure	Time frame
Safety & efficacy of deep TMS in children & adolescent population as assessed by TMSens_Q & reduction in score of Childrenâ??s Yale-Brown Obsessive-Compulsive Scale (CY-BOCS).Timepoint: Safety & efficacy of deep TMS in children & adolescent population as assessed by TMSens_Q & reduction in score of Childrenâ??s Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) after 2 weeks of dTMS treatment .	—

Secondary

Measure	Time frame
fMRI task-based assessment of difference in functional connectivity between mPFC & ACC at baseline and after application of deep TMS and reduction in scores of severity of clinical global inventory.Timepoint: Secondary outcome variables are fMRI task-based assessment of difference in functional connectivity between mPFC & ACC at baseline and after application of deep TMS and reduction in scores of severity of clinical global inventory after 2 weeks of dTMS treatment.	—

Measure

Time frame

fMRI task-based assessment of difference in functional connectivity between mPFC & ACC at baseline and after application of deep TMS and reduction in scores of severity of clinical global inventory.Timepoint: Secondary outcome variables are fMRI task-based assessment of difference in functional connectivity between mPFC & ACC at baseline and after application of deep TMS and reduction in scores of severity of clinical global inventory after 2 weeks of dTMS treatment.

—

Countries

India

Contacts

Public ContactDr Nishant Goyal

Central Institute of Psychiatry

psynishant@gmail.com9431171162

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026